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INTRODUCTION
The main role of our diet is to provide sufficient macro- and
micronutrients to satisfy our needs for energy, growth, and
development. During the past decades, the concept of
“functional foods” has emerged, implying that some foods
or its components are biologically active and can regulate
various body functions, thereby being beneficial to health
and reducing the risk of several diseases. Dietary fibre, an
essential part of the human diet, consists of many sub-
stances of plant origin that are not digested in the human
upper gastrointestinal tract, including polysaccharides such
as cereal -glucans, arabinoxylans and cellulose. Starch is
not a part of dietary fibre, because it is hydrolysed by en-
zymes and absorbed in the small intestine. Dietary fibre reg-
ulates the rate of nutrient digestion and absorption, serves as
a substrate for the gastrointestinal microflora of the gut and
promotes laxation. The fibre affects gastrointestinal func-
tion through properties including viscosity, water holding
capacity, bulk, fermentability and binding of bile acids
(Schneemann, 1987). An important feature of fibre is to re-
duce the rate of absorption of nutrients. One effect of fibre
is conversion of carbohydrate components into a slow re-
lease form that requires less insulin and also increases the
elimination of bile acids. Fibre also alters the colonic
short-chain fatty acid profiles (Jenkins et al., 2001). Oats
(Avena sativa) are cereals rich in dietary fibres, antioxi-
dants, proteins and unsaturated fat, which makes them inter-
esting as functional food ingredients (Sangwan et al., 2014).
As the most common component of oats to be searched and
studied are -glucans. Therefore our literature review will
be focused on oat -glucan and its impact on the gastroin-
testinal tract. We searched for articles in the PubMed data-
base describing studies with oat-based products and gastro-
intestinal tract. The search was limited to full-text English
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Oat is rich in valuable nutrients. In comparison to other cereals, oat contains more total proteins,
carbohydrate, fat, non-starch fibre, as well as unique antioxidants (one of them – avenanthra-
mides), vitamins, and minerals. One of the most often studied components of oats is -glucan —
a type of soluble dietary fibre located throughout the starch endosperm, but with highest concen-
tration in the bran. Many studies have shown the beneficial health effects of oat -glucan as a sol-
uble dietary fibre. Until now, most of the studies on this nutrient have been conducted in the
cardiovascular and diabetology field. This article aimed to review the literature on studies that in-
vestigated the effects of oat-based products on human gastrointestinal tract — gastrointestinal
microflora, irritable bowel syndrome, inflammatory bowel disease as well as prevention/treatment
of colorectal cancer. A literature search was conducted using PubMed database. More than 80
potential articles were identified, which were selected afterwards according to aims of our study.
Studies done on human were preferred. A long-term dietary intake of oat-based products im-
proves human intestinal microflora, could have benefits in irritable bowel syndrome, and probable
effects were seen in patients with ulcerative colitis, but this remains to be proven. There are few
studies regarding prevention/treatment of colorectal cancer and they do not show clear benefit
nor provide recommendations.
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bowel disease, colorectal cancer.
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language articles, including review articles and meta-analy-
ses. The studies were carried out mostly in humans, but
some of the studies conducted in vitro and animals also in-
cluded. Additional articles were identified by searching
titles of references in relevant articles obtained from a data-
base search.
OAT -GLUCAN. MOLECULAR STRUCTURE
Oat consists of germ, endosperm and bran, which is rich in
valuable nutrients. In comparison to other cereals, oat con-
tains more total proteins, carbohydrate (may reach up to
75–80%), fat, non-starch fibre, as well as unique antioxi-
dants (one of them — avenanthramides), vitamins, and min-
erals (Brand et al., 1996; Peterson et al., 1997). One of
the most often studied components of oats is -glucan
((13),(14)--D-glucan) — a type of soluble dietary fi-
bre, which is located throughout the starch endosperm, but
with the highest concentration in bran (Fig. 1). It contrib-
utes 3.6–5.1% of dry weight of the oat whole grain (Hamp-
shire, 2004). Many studies have shown the beneficial health
effects of oat -glucan as a soluble dietary fibre. Until now,
most of the relevant studies have been conducted in the car-
diovascular and diabetology field. Consuming oats lowers
the level of blood cholesterol and attenuates postprandial
glucose response. A new meta-analysis published in the
American Journal of Clinical Nutrition in 2014 shows that
daily consumption of at least 3 g oat -glucan reduces cho-
lesterol levels. This effect was observed in lean, overweight
and obese male and female adults, with and without type 2
diabetes, across 28 randomised controlled trials (Whitehead
et al., 2014). The Food and Drug Administration (FDA) of
the USA has accepted a health claim in which it is stated
that a daily intake of 3 g of soluble oat -glucan can lower
the risk of coronary heart disease (FDA, 1997). The evi-
dence presented indicates that the cholesterol-lowering ef-
fect of oat beta-glucan may depend on the increased viscos-
ity in the small intestine, which reduces reabsorption of bile
acids, increases the synthesis of bile acids from cholesterol,
and reduces circulating (LDL) cholesterol concentrations.
Oat -glucan has a capacity to form highly viscous solu-
tions. The hypocholesterolemic effect of -glucan was re-
lated to the elevation of intestinal viscosity caused by
-glucan. Viscosity in the small intestine is determined by
the concentration, molecular weight (MW) and solubility of
oat beta-glucan (Wood et al., 1991). This is supported by a
recent randomised clinical trial (RCT) that showed a re-
duced cholesterol lowering efficacy of oat -glucan with
low MW (210 kDa) compared to high MW (>2000 kDa) or
medium MW (530 kDa) oat -glucan (Wolever et al.,
2010). Oats also reduce the glucose and insuline responses.
From molecular point of view, oat -glucan is a linear
polysaccharide that consists only of -D-glucopyranosyl
units (Fig. 2). These units are joined by either (13)- or
(14)--D-linkages, hence the name mixed-linkage
(13),(14)--D--glucan. The distribution of the individual
(13)– 22 and (14)-linkages is not random, nor is it regular.
The (14)--links occur mostly in groups of two or three and
are separated by a single (13)-link, as first reported by
Parrish et al. in 1960 and later on by others (Reese et al.,
1962). The building blocks, 1.3-linked cellotriosyl and
–cellotetraosyl units constitute over 90% of the molecule
(Wood et al, 1994). The (13)-link prevents close packing
of the molecule and makes the molecule partly soluble in
water, unlike cellulose, which is built entirely of
-(14)-linked D-glucanosyl units and is capable of close
packing to crystalline structures. To summarise, cellulose is
a (14)--D-glucan, where the -glucoside bond makes
the cellulose indigestable and insoluble. The mixed linked
(13),(14)--D-glucan is composed of (14)-linked
glucose units with a single (13)-linked glucose every
two or three units. It is the (13) linkages that make
-glucans soluble (Johansson, 2006). 20% of oat and 46%
of barley -glucan is insoluble (Aaman et al., 1987).
The structure and properties of oat -glucan vary between
species and varieties of oats, and are also affected by the
growing and storage conditions and processing of oat grain.
In addition, the extraction and analysis methods may also
contribute to the variations in the structure, molecular
weight (Wang et al., 2014).
Fig. 1. Location of -glucan in oat grain (www.oatsandhealth.org).
Fig. 2. Molecular structure of oat -glucan.
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OATS AS PREBIOTICS, ITS INFLUENCE ON INTESTI-
NAL MICROFLORA
In humans, intestinal microbiota plays an important role in
the maintenance of host health by providing energy, nutri-
ents, and immunological protection. The composition of the
intestinal microbiota plays a significant role in human im-
munology, nutrition and pathological processes (Zoetendal
et al., 2004). Describing the complexity and ecology of the
intestinal microbiota is important for defining its effects on
overall human health. Human intestinal microbiota under-
goes maturation from birth to adulthood and is further al-
tered with ageing. The major bacterial groups are Clostrid-
ium leptum, Clostridium coccoides, Bacteroidetes and
Escherichia Coli. In healthy adults, 80% of the identified
fecal microbiota can be classified into three dominant
phyla: Bacteroidetes, Firmicutes and Actinobacteria. In
general terms, the Firmicutes to Bacteroidetes ratio is re-
garded to be of significant relevance in human gut microbi-
ota composition. Although the intestinal microbiota is rela-
tively stable throughout adult life, recent studies indicated
that modifications occur in the composition in elderly indi-
viduals. For example, a reduction in the numbers of Bifido-
bacteria and Bacteroides has been observed, accompanied
also by a decrease of Lactobacilli. The major functions at-
tributed to the microbiota present in the gut begin to mani-
fest at the end of the second year of life and comprise: i) nu-
trients absorption and food fermentation; ii) stimulation of
the host immune system, and iii) barrier effects against
pathogens. The majority of microbiota are anaerobic, and
although more than 50 bacterial phyla have been described,
only four predominate in the mammalian GI tract: Bacteroi-
detes, Firmicutes, Actinobacteria, and Proteobacteria. Of
these, Bacteroidetes and Firmicutes account for more than
90% of the bacteria in the human GI tract (Eckburg et al.,
2005; Mariat et al., 2009). It is estimated that approximately
4000 bacterial species reside in human GI tracts, comprising
as many as 1014 bacterial cells, a number 10 times greater
than the number of cells in the human body. Per gram of
content, there is a marked and progressive distal increase in
the number of bacteria: 101 in the stomach, 103 in the duo-
denum, 104 in the jejunum, 107 in the ileum, and 1012 in the
colon (Sekirov et al., 2010). Probiotics are live microorgan-
isms, which when administered in adequate amount, confer
a health benefit on the host. Prebiotics are non-digestible
food ingredients that beneficially affect the host by selec-
tively stimulating the growth or activity of one or a limited
number of bacteria in the colon and thus improve host
health (Gibson et al., 1995).
Oats, besides a high content of -glucans, also contain
arabinoxylans and cellulose, which are mainly insoluble fi-
bre. The fibres are not digested in the small intestine, but
the soluble -glucan is believed to increase the viscosity of
the food bolus, leading to a slower gastric emptying, en-
hanced gut fill and slower absorption of nutrients. All these
mentioned factors contribute to stimulation of growth of hu-
man microflora. In a study from Romania and Italy, oat
bran extract added to milk selectively promoted the number
of probiotic bacteria (Lactobacillus rhamnosus, Lacto-
bacillus paracasei, and also their combination SYNBIO) in
milk and maintained overall microbial counts over a 28-day
storage period with respect to controls (whole milk without
substrates). Therefore, a new synbiotic product (combina-
tion of prebiotics and probiotics) was developed. The
probiotic strains were recovered from fecal samples from 40
volunteers fed for 4-week period (Coman et al., 2013). Oats
have been shown to increase the proportion of short chain
fatty acid (SCFA) butyrate, which has regulatory functions
in cell proliferation and differentiation. -glucan, however,
leads mainly to the production of another SCFA — propio-
nate, which is suggested as one of the mechanisms for
the cholesterol lowering effects of oats and other
-glucan-containing products (Wolever et al., 1991). Simi-
lar results were obtained in a study in Greece (Mantzou-
ridou et al., 2013). A study in the United Kingdom (Kedia
et al., 2009) showed that oat bran fraction added to human
fecal cultures decreased culturable anaerobes and clostridia
and promoted increase in bifidobacteria and lactobacilli
populations.
Fermentable dietary fibre is the most important source for
formation of SCFA in the large intestine. Beta-glucans, pec-
tin and resistant starch are fermented to 70–100 %, whereas,
for example, cellulose is usually not fermented at all. The
major SCFAs produced after fermentation of dietary fibres
are acetate, propionate and butyrate. Certain colonic bacte-
ria generate energy from these fermentation products. The
properties of the microflora and the composition of the sub-
strate (dietary fibre) are important factors both for the total
and individual SCFA formed. The SCFAs are physiologi-
cally active in different ways. Acetate is readily taken up
from the intestine and transported to the liver, where it can
serve as a substrate for cholesterol biosynthesis. Butyrate
serves as a fuel for epithelial cells and can also regulate cell
proliferation and differentiation. Recently, butyrate was
suggested to have influence on lipid metabolism by regula-
tion of intestinal fat absorption. Propionate may contribute
to hypocholesterolemic action by either inhibiting
HMG-CoA reductase or by preventing utilisation of acetate
for cholesterol synthesis. A substantial amount of bacteria is
present in the ileum, but the vast majority of bacteria exist
in the proximal large bowel, where fermentation also takes
place. It is in the caecum and ascending colon that the
SCFA production reaches its highest concentration in hu-
mans. At both the colonic and systemic levels, fermentation
and especially SCFA production play an integral role. Co-
lonic epithelial cells preferentially use butyrate as an energy
source, even when competing substrates such as glucose
and glutamine are available. Butyrate is considered a key
nutrient determining the metabolic activity and growth of
colonocytes and may function as a primary protective factor
against colonic disorders, although data on this topic are
conflicting (Andersson, 2009). SCFAs are water-soluble
and are absorbed into the blood stream. The brain, muscles,
and tissues metabolise acetate systemically, whereas propio-
nate is cleared by the liver and may lower the hepatic pro-
duction of cholesterol by interfering with its synthesis.
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Transport to and further metabolism of SCFAs in the liver,
muscle, or other peripheral tissues is thought to contribute
about 7–8% of host daily energy requirements (Cummings
et al., 1991). Fermentation and SCFA production also in-
hibit the growth of pathogenic organisms by reducing
luminal and fecal pH. Low pH reduces peptide degradation
and the resultant formation of toxic compounds, such as
ammonia, amines, and phenolic compounds, and decreases
the activity of undesirable bacterial enzymes (Thornton,
1981; Smith et al, 1996). The gastrointestinal microbiota
plays important roles in health and disease, but the diversity
of the microbiota is poorly defined and yet far from com-
pletely characterised. In another study from Ireland and UK,
although -glucans displayed no apparent prebiotic poten-
tial, it significantly modulated the microbial communities
and the resulting SCFA (51 : 32 : 17; acetate : propionate :
butyrate) profile. Acetate was the most prevalent SCFA in
all treatments; accounting for 44% of the SCFA produced
with the -glucan treatments; 67.3% in the no treatment
control, and 63.3% with inulin, at 48 h. However, fermenta-
tion of -glucan resulted in higher total amounts and pro-
portions of propionate; ranging from 30% with 150-kDa oat
-glucan treatment, to 37.1% with 172-kDa barley-glucan,
at 48 h. This study revealed that the main group of human
faecal microbial communities involved in -glucan fermen-
tation was the C. histolyticum group, and to a lesser extent
Clostridia cluster IX and the Bacteroides–Prevotella and
Atopobium groups (Hughes et al., 2008).
ß-GLUCANS AND IRRITABLE BOWEL SYNDROME
(IBS)
One of the most common gastrointestinal diseases of the
world is IBS, affecting 8–22% and accounting for 20–50%
of referrals to gastroenterology clinics. It is characterised by
abdominal pain, excessive flatus, variable bowel habit and
abdominal bloating for which there is no evidence of detect-
able organic disease (Madden et al., 2002). Although the
pathogenesis is still not fully understood, one of the popular
theories is altered gastrointestinal microflora, as some bac-
teria are more prone to gas production than others. In a
study, 60 IBS patients were randomised in two groups: for a
period of four weeks one group received rose-hip drink con-
taining Lactobacillus plantarum and oat flour, and the other
group were given plain rose-hip drink. The results of
the study showed that patients receiving Lactobacillus
plantarum and oat flour drink had decreased pain and flatu-
lence compared with the placebo group. Therefore,
probiotic therapy with oat fibre (as prebiotics) could be one
of the treatment options in patients with IBS. Although fibre
content of the test solution was minimal and it is unlikely
that the fibre content could have had any effect, this type of
probiotic therapy warrants further study in IBS patients
(Nobaek et al., 2000). In a study from Italy, 50 patients with
IBS received pills made from beta-glucans and inositol
(Biointol™) for four weeks. Patients who were treated with
Biointol significantly decreased abdominal bloating, flatu-
lence and abdominal pain, with a slightly increasing ur-
gency of bowel movements, compared with the placebo
group (Ciacci, 2011). Other studies showed similar decrease
of gastrointestinal symptoms after probiotic therapy, but
without oat-based product addition (Guyonnet et al., 2007;
Kajander et al., 2008). These studies stressed the possible
role of altered gastrointestinal microflora in pathogenesis of
IBS as well as role of prebiotics, including oat -glucans
and probiotics in the treatment of IBS.
ß-GLUCANS AND INFLAMMATORY BOWEL DIS-
EASE (IBD)
IBD are two related chronic inflammatory disorders charac-
terised by acute flares followed by remission: ulcerative co-
litis (UC) and Crohn’s disease (CD). UC affects the inner
lining of the colon, which becomes inflamed and develops
ulcers. UC generally involves the distal part of the colon,
but may progress proximally to pancolitis. CD tends to in-
volve the entire bowel wall and commonly affects the termi-
nal ileum and parts of the colon, but may affect any part of
the gastrointestinal tract. A major complication of CD, af-
fecting many CD patients is the formation of fistulas and
stenosis (Feldman et al., 2010). Furthermore, UC and CD
may be considered systemic disorders, as around 6–47% of
IBD patients experience extraintestinal complications. The
organs most commonly involved include skin, eyes, joints,
biliary tract and lungs (Rothfuss et al., 2006). The incidence
of IBD varies considerably worldwide with incidence rates
between 0.5–24.5/105 and 0.1–16/105 inhabitants for UC
and CD. The highest rates are reported in Northern and
Western Europe as well as North America (Lakatos, 2006).
The etiology and pathophysiology of both UC and CD is
complex. Accumulating evidence suggests that an inappro-
priate immune response to non-pathogenic microbes of the
intestine and other luminal antigens plays a critical role in
the initiation and pathogenesis of IBD. The increased IBD
incidence over the past decades, particularly in developing
countries, suggests that environmental factors are impli-
cated in IBD development, although there is evidence about
genetic susceptibility as well (Feldman el al., 2010).
IBD is associated with overexpression of pro-inflammatory
cytokines, including TNF-, interferon (IFN), IL-1 and
IL-6. CD and UC have been considered to be Th1- and
Th2-driven diseases, respectively, although the picture now
appears more complex. Th17 cells, a distinct subset of
CD4+ Th cells characterised by abundant IL-17 production,
are associated with intestinal inflammation and tissue pa-
thology and have attracted considerable attention recently.
A cytokine IL-23, is central in promoting Th17 cells. The
above mentioned cytokines and their producers may prove
to be attractive therapeutic targets (Gálvez, 2014; Maloy et
al., 2008). IBD is routinely treated with antibiotics,
immunosuppressive and anti-inflammatory drugs. Prom-
ising antibody-based therapeutics that block key cytokines
and interfere with T cell activation and migration of inflam-
matory cells have emerged as potent alternative therapies
for IBD. Although these strategies may prove effective,
available therapeutics are associated with considerable ad-
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verse reactions, including opportunistic infections. Patients
with severe IBD, refractory to medical treatment or with
neoplastic transformation, require surgery. For selected
cases (proctocolectomy in UC and ileocolonic resection in
Crohn’s disease), minimally invasive surgery can be the
treatment option with speeding recovery, reducing costs and
decreasing morbidity (Polle et al., 2007). Surgery continues
to have an important role in IBD treatment, as 30–40% of
UC patients and 70% of CD patients require surgical inter-
vention at some point. Total colectomy, the only cure for
UC, is indicated in approximately 25% of UC patients
(Surlin et al., 2012). Notably, as many as 40–60% of IBD
patients respond poorly to current standard therapy, indicat-
ing a considerable need for new, more effective and safe
therapies (Katz, 2007).
Regarding ethiopathology of IBD, which is still under in-
vestigation, several studies have reported that IBD is associ-
ated with impairment in SCFA production, mainly acetate,
propionate, and butyrate. They are produced in the large
bowel by anaerobic bacterial fermentation of undigested
dietary carbohydrates and fibre polysaccharides, with bu-
tyrate being considered as the major fuel source for colono-
cytes. These SCFAs have been proposed to play a key role
in the maintenance of colonic homeostasis. Therefore, it is
reasonable to consider therapeutic approaches that increase
colonic SCFA production, as can be achieved by admini-
stration of dietary fibre to IBD patients, including oats.
There is mounting evidence that carboxylic acids (CAs)
formed by colonic fermentation of indigestible carbohy-
drates have positive health effects. In this context, butyric
acid and, to some extent, propionic acid have mainly been
emphasised. These acids are important energy sources for
the colonocytes and may thus improve the condition of the
colonic mucosa and, in consequence, decrease the risk of
mucosal lesions. Especially butyric acid has been suggested
to play a role in the prevention and treatment of colonic dis-
eases, such as ulcerative colitis and colon cancer, and to
some extent Crohn’s disease. Carboxylic acids (CAs), espe-
cially butyric acid, have been suggested to counteract colo-
nic diseases, such as ulcerative colitis and colon cancer. Un-
fortunately, there is quite limited documentation of efficacy
of dietary fibre in properly designed trials (Galvez, 2005).
In the 1990s, a popular study direction was SCFA topical
treatment in distal ulcerative colitis, most of which showed
positive results (Breuer et al., 1991; Steinhart et al., 1996).
Comparing butyrate, which mostly has been investigated,
with two other SCFA, namely acetate and propionate,
which have less well-documented effect on inflammation, a
study in Sweden proved that propionate and butyrate were
equipotent, whereas acetate was less effective, but still use-
ful in the treatment of IBD (Tedelind et al., 2007). A study
from Italy showed good results with 4 g/day butyrate as en-
teric coated tablets for 8-week treatment of mild-moderate
ileocolonic Crohn’s disease. This therapy was safe and well
tolerated and 53% of patients achieved remission (Di Sa-
batino, 2005).
Most studies on colonic microbiota have focused on fecal
material, although increasing evidence suggests that the
epithelial surface is also colonised by large and diverse bac-
terial communities, which are structurally distinct from
those that live in gut lumen. These mucal communities can
change markedly in inflammatory conditions, such as in-
flammatory bowel disease. Importantly, the composition of
these mucosal communities in humans can be manipulated
through the use of prebiotics (Macfarlane et al., 2004).
ß-GLUCANS AND COLORECTAL CANCER
Non-prescriptional use of medicinal herbals among cancer
patients has been known around the world. Some
chemotherapeutic drugs, like vincristine and taxol, are puri-
fied from herbs. -glucans are believed to have various
imunomodulatory properties. Studies in vitro and in vivo re-
vealed that the immunostimulating activity of -glucan de-
pends on structure, molecular weight and number of
branches. Based on in vitro studies, -glucans act on several
immune receptors, including Dectin-1, which is one of
better known and studied. There are some limitations of
those studies, for example, there are no available -glucan
control standards with specific molecular weight and
branches. Most of the -glucans used in research are based
on extracts rather purified -glucans, and therefore it is not
possible to exclude confounding factors. The exact immu-
nological action and signalling pathway are still unclear and
have to be further defined (Chan et al., 2009). -glucans
from various sources possess different characteristics and
-glucans with additional branching have the highest
immunostimulating activity (Freimund et al., 2003). There-
fore, until now most studies in oncology have used
-glucans isolated from yeasts. Searching through PubMed,
there are few studies regarding use of oat -glucans in pre-
vention or treatment of colorectal cancer. One of them, con-
ducted on 25 healthy subjects in Sweden, suggested that di-
etary supplementation with oat bran (40 g -glucan
enriched) per day can serve as an excellent source of car-
boxyl acids. After 8 and 12 weeks, the fecal concentrations
of acetic, propionic and isobutyric acid were higher com-
pared with values at entry. Oat bran may therefore have a
preventive potential in regard to colonic diseases (Nilsson et
al., 2007). Although the studies until now performed have
shown positive results from ß–glucan and its metabolites —
CA, on intestinal epithelium, there is one study from Can-
ada, Ontario, with opposite results. The aim of that study
was to determine whether -glucan from oats can shield in-
testine epithelial cells from oxidative cell injury. The study
was done on rat small intestine epithelial cells, which were
cultured with or without medium viscosity oat -glucan at
various concentrations and treated with serial diluted H2O2.
The activity of inflammatory substances (superoxide dis-
mutase activity, expression of TNF-, activity of caspase-3)
was increased by H2O2 only under the higher concentration
of -glucan. Therefore, the study revealed that low levels of
-glucan do not appear to protect small intestine epithelial
cells against H2O2 induced oxidative injury, while applica-
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tion of higher doses of this soluble fibre promoted oxidative
cell injury induced by H2O2. This study expands the current
understanding regarding dietary soluble fibre and intestine
health and disease, suggesting that oat -glucan creates a
negative challenge to intestinal mucosa cells and may act in
synergy with oxidative cell injury induced by reactive oxy-
gen species. However, as this study was conducted on ani-
mals, further studies in humans are necessary to prove or re-
ject this unexpected result.
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AUZU PRODUKTU IETEKME UZ CILVÇKA GASTROINTESTINÂLO TRAKTU
Auzâs ir daudz vçrtîgu barîbas vielu. Salîdzinot ar citiem graudaugiem, tâs satur vairâk kopçjo olbaltumvielu, ogïhidrâtu, tauku, ne-cietes
ðiedrvielas, daþus unikâlus antioksidantus (viens no tiem – avenantramîdi), vitamînus un minerâlvielas. Viena no visbieþâk pçtîtajâm auzu
sastâvdaïâm ir -glikâni. Tâ ir ðíîstoða ðíiedrviela, kas atrodas auzu graudâ, visvairâk — grauda ârçjâ daïâ. Daudzos pçtîjumos ir pierâdîta
-glikânu labvçlîgâ ietekme uz cilvçka veselîbu. Visvairâk pçtîjumu ar -glikâniem ir veikti kardioloìijâ un diabetoloìijâ. Ðis apskatraksts
ir veltîts pçtîjumiem par auzu -glikânu ietekmi uz cilvçka gastrointestinâlo traktu: gastrintestinâlo mikrofloru, kairinâtu zarnu sindromu,
iekaisîgâm zarnu slimîbâm un kolorektâla vçþa profilaksi/ârstçðanu. Literatûras apskatâ izmantoti pçtîjumi no PubMed datu bâzes. Tika
atlasîti vairâk kâ 80 pçtîjumi un apskatraksti, kas veltîti ðai tçmai, no kuriem tâlâk pârsvarâ analizçti pçtîjumi, kas veikti ar cilvçkiem.
Ilgstoða auzu produktu lietoðana uzturâ labvçlîgi ietekmç gastrointestinâlo mikrofloru. Iespçjama labvçlîga ietekme uz slimîbas gaitu
novçrota kairinâtu zarnu sindroma slimniekiem. Èûlainâ kolîta gadîjumâ -glikâni, iespçjams, samazina iekaisumu zarnâs, tomçr ir
nepiecieðami tâlâki pçtîjumi, kas ðo efektu apstiprinâtu. Kolorektâla vçþa profilaksei/ârstçðanai ir veikti pârâk maz pçtîjumu, lai izdarîtu
secinâjumus un sniegtu rekomendâcijas par profilaksi/ârstçðanu.
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